Papers
2
Total Citations
27
H-Index
2
About
C. Feiler is a structural biologist whose work centers on advancing crystallographic fragment screening—a powerful technique for identifying small-molecule starting points in early-stage drug discovery. Their major contribution lies in developing and optimizing the workflow and tools for fragment screening at the Helmholtz-Zentrum Berlin, a leading synchrotron facility. This work has enabled researchers to efficiently screen large libraries of fragments against protein crystals, leveraging high-resolution X-ray diffraction to detect weak but specific binding events. Feiler’s most cited paper, published in 2021, has garnered 18 citations, underscoring its practical value in the structural biology community. A second related publication adds 9 more citations, reflecting sustained interest in their methodological innovations. By streamlining the screening pipeline—from crystal handling to data analysis—Feiler has helped make crystallography one of the most preferred methods for fragment-based ligand design. Their achievements are particularly notable for bridging the gap between synchrotron capabilities and the needs of academic and pharmaceutical researchers, accelerating the identification of novel chemical probes and potential therapeutics. For students and researchers entering structural biology, Feiler’s work exemplifies how method development can have a direct, tangible impact on drug discovery.
Research Focus
Key Achievements
Top Papers
- 1
- 2